Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Is CelLBxHealth plc (CLBX) a Sleeper Stock Investors Should Be Watching in 2026?

The question for 2026 is whether the reset is working. Half-year results on 15 July 2026 showed the operating loss cut by 72%, cash runway into Q2 2027 and a reiterated target of at least £2.1m ofRevenuethis year. But the board also disclosed a …

Divya Sood | 10 September 2026

Why Aptamer Group Plc (APTA) Deserves a Fresh Look as Its Pipeline Heats Up

The question is whether a still loss-making business can convert that momentum into the higher-marginRoyaltystreams management has promised before the cash raised in April 2026 runs down. With in vivo radiopharmaceutical data due by the end of 2026 and a new joint broker appointed, …

Ankur Sharma | 10 September 2026

Shield Therapeutics Plc (STX) in Focus: Is This a Biotech Story the Market Is Underestimating?

The deal lands a week after interim results showing Shield's first operating profit, and a month after the shares hit a 52-week low of 3.70p. With the stock at around 6p and aMarket Valueof roughly £64m, the question is whether aBusinessgenerating $30m of half-year …

Divya Sood | 10 September 2026

Why SkinBioTherapeutics Plc (SBTX) Deserves a Fresh Look After Its AIM Suspension Was Lifted

The underlying business, which sells foot-care products through Boots, Superdrug and the NHS, AxisBiotix gut-skin supplements and contractManufacturingservices, grew revenue by 37% in the first half of its financial year. The question is whether that operational story can now be separated from the governance …

Divya Sood | 10 September 2026

Why Feedback plc (FDBK) Deserves a Fresh Look as a National NHS Decision Nears

The key question is whether the NHS, after restructuring that management has called the toughest trading conditions it has known, finally converts years of pilots into a contract of scale — and whether Feedback's cash, guided to last only to mid-2027, holds out long …

Ankur Sharma | 10 September 2026

OptiBiotix Health PLC (OPTI): Could the Next Clinical or Commercial Catalyst Transform the Story?

The question is whether these wins, together with a first NHS clinical trial for WellBiome and the long-awaited demonstration of its SweetBiotix sugar substitute, can move a business that still lost £3.9m before tax in 2025 on revenue of £1.2m, and whose runway has …

Ankur Sharma | 10 September 2026

Why hVIVO plc (HVO) Deserves a Fresh Look as Its Orderbook Heats Up

For a company until recently almost synonymous with human challenge trials, the shift to a broader clinical development platform is the key question. With the shares at roughly 8.4p and aMarket Capitalisationnear £58m, according to lse.co.uk on 2 September 2026, the market values hVIVO …

Divya Sood | 10 September 2026

Avacta Group PLC (LSE:AVCT) in Focus: What Could Trigger the Next Big Move?

The key question is timing. Avacta said in May 2026 that its cash runway stretches only into early Q1 2027, and its accounts flag a material uncertainty over going concern. With first AVA6103 data promised for late 2026 and partnering talks unsigned, the gap …

Ankur Sharma | 10 September 2026

Is GENinCode PLC (LSE:GENI) a Sleeper Stock Investors Should Be Watching in 2026?

Yet the newsflow has not been uniformly bleak. On 28 August 2026 the company published real-world results from an 18-month pilot of its CARDIO inCode-Score polygenic risk test in Catalonia, presented at the European Society of Cardiology Congress in Munich. With a fresh USFood …

Ankur Sharma | 10 September 2026

Verici Dx Plc (VRCI): The London-Listed Story That Could Surprise the Market Next

The question is whether that commercial momentum can outrun the balance sheet. The FY25 accounts, published on 29 June 2026, carry a material uncertainty over going concern: the directors say further funding is needed before the end of 2026, even after a £2.6mEquityraise at …

Divya Sood | 10 September 2026
Support

Hi! How can we help you today?

Loading…